Sirtuins and resveratrol in heart and kidney disease: a narrative review of mechanisms and therapeutic potential.
Sirtuins and resveratrol in heart and kidney disease: a narrative review of mechanisms and therapeutic potential.
Sirtuins and Resveratrol in Cardiorenal Diseases: A Narrative Review of Mechanisms and Therapeutic Potential
Abstract:
Aging is a very complex process. and is linked to the enzyme sirtuin. Sirtuin enzymes are a class of deacetylases involved in caloric restriction and aging by altering energy metabolism. Genome stability and resistance to stress until now Seven sirtuins have been identified. The aim of this review article was to analyze literature published between January 2005 and March 2025 to assess the role of sirtuins in chronic kidney disease. And because heart disease and kidney disease are closely related. To explore the role of sirtuins in heart disease and communication between the heart and kidneys. A reciprocal relationship between chronic kidney disease and aging appears to exist. This is because chronic kidney disease may contribute to premature biological aging of many organ systems. Sirtuin enzymes are involved in the pathophysiology of kidney disease. Stimulating these enzymes can slow the progression of many kidney diseases. What is noteworthy is There are a growing number of studies linking sirtuin enzymes to various cardiovascular diseases. SIRT affects the production of free radicals (ROS) in the mitochondria by modulating mitochondrial function. Imbalance in SIRT levels may increase the risk of cardiovascular disease. SIRT has been implicated in the pathophysiological mechanisms of HFpEF (HFpEF) through different signaling pathways. Fibrosis is the mechanical link between the heart and kidneys in the development of heart and kidney disease. Current studies on sirtuins, resveratrol, and heart and kidney disease. Highlights its potential therapeutic benefits in controlling blood pressure. Kidney function, lipid profile, and inflammation make it a promising research area for improving cardiovascular and kidney health outcomes, however, important gaps remain. The limited availability of highly specific and efficient sirtuin modulators hinders their clinical application. This is because most of the existing compounds have low bioavailability and inappropriate pharmacokinetic properties.